Introduction {#S1}
============

Mammalian hearing function relies upon active cochlear amplification amplifying the basilar membrane (BM) vibration to acoustic stimulation increasing hearing sensitivity and frequency selectivity \[[@R1]--[@R2]\]. Outer hair cell (OHC) electromotility is an active cochlear amplifier in mammals \[[@R3]--[@R6]\]. Deficiency of OHC electromotility can induce hearing loss \[[@R7]\]. *In situ*, OHCs are constrained by phalangeal processes of Deiters cells (DCs) and pillar cells (PCs). They contain rigid bundles of microtubules and actin microfilaments along their phalangeal processes acting as a scaffold supporting OHCs standing between the BM and the reticular lamina (RL) \[[@R8]--[@R9]\]. This rigid scaffold also transfers forces between the BM and the RL and provides an appropriate mechanical load to the OHCs to maintain OHC electromotility at an optimal operating point.

It has been found that the phalangeal processes of DCs can alter their curvature in responses to electrical and chemical stimulations \[[@R10]--[@R12]\]. However, DCs do not have OHC-like electromotility. DCs and PCs including their phalangeal processes are well-coupled by gap junctions but hair cells have neither gap junctions nor connexin expression \[[@R6], [@R13][@R14][@R15]\]. There is also no direct electrical conductance between DCs and OHCs \[[@R15]--[@R16]\]. We previously found that electrical and mechanical stimulations in DCs or alternation of gap junctions between DCs can affect OHC electromotility in the *in vitro* preparation \[[@R16]\]. However, it remains unclear whether supporting cell gap junctions *in vivo* can also alter active cochlear mechanics to influence hearing.

Connexin 26 (Cx26, *GJB2*) is a predominant gap junction isoform in the cochlea \[[@R13], [@R14],[@R17]\]. In this study, we selectively deleted Cx26 expression in DCs and outer pillar cells (OPCs), which directly constrain OHCs standing on the BM. We found that targeted-deletion of Cx26 in DCs and OPCs left-shifted OHC electromotility and reduced active cochlear mechanics with hearing loss. These data demonstrate that Cx26 expression in supporting cells plays a critical role in active cochlear amplification *in vivo*. In the clinic, Cx26 mutations produce a high incidence of hearing loss and are responsible for \~50% of nonsyndromic hearing loss \[[@R18]--[@R20]\]. We recently found that cell degeneration is not a primary cause for deafness due to Cx26 deficiency \[[@R21]\]. These new findings also reveal a new mechanism for Cx26 deficiency associated hearing loss.

Results {#S2}
=======

Targeted-deletion of Cx26 in DCs and OPCs in the cochlea {#S3}
--------------------------------------------------------

We used loxP-Cre technique to delete Cx26 expression in DCs and OPCs. The Cx26 conditional knockout (cKO) mouse was generated by crossing *Cx26^loxP/loxP^* transgenic mice \[[@R22]\] with a *Prox1-CreER^T2^* mouse line, which a tamoxifen-inducible Cre recombinase is driven by a homeodomain transcription factor Prox1 \[[@R23]\]. Prox1 is specifically expressed in DCs and OPCs in the cochlea after E18 and remains in these cells after birth \[[@R24]--[@R26]\]. Consistent with Cre expression \[[@R26]\], Cx26 labeling in DCs and OPCs was absent in Cx26 cKO mice ([Fig. 1](#F1){ref-type="fig"}, [Supplementary Fig. S1 and S2](#SD1){ref-type="supplementary-material"}). Cx26 labeling in the inner layer of Hensen cells was also reduced but not absent ([Fig. 1b--c, g--h](#F1){ref-type="fig"}). The deletion is uniform at apical, middle, and basal turns ([Supplementary Fig. S1](#SD1){ref-type="supplementary-material"}). Cx26 labeling in other cochlear structures including the spiral limbus (SLM) and the lateral wall was intense and normal ([Figs. 1a--e](#F1){ref-type="fig"} and [Supplementary Fig. S2](#SD1){ref-type="supplementary-material"}). Cx30 is another predominant gap junction isoform expressed in the cochlea \[[@R14], [@R15]\]. Cx30 expression also appeared normal in Cx26 cKO mice. Intense-labeling for Cx30 in DCs and OPCs is visible ([Figs. 1c&h](#F1){ref-type="fig"} and [Supplementary Fig. S2](#SD1){ref-type="supplementary-material"}). In addition, the cochlea appeared normal development in Cx26 cKO mice ([Figs. 1e](#F1){ref-type="fig"} and [Supplementary Fig. S1](#SD1){ref-type="supplementary-material"}).

Elevation of auditory brainstem response threshold {#S4}
--------------------------------------------------

The Cx26 cKO mice had hearing loss ([Fig. 2](#F2){ref-type="fig"}). The ABR threshold in homozygous Cx26 cKO mice was increased significantly. The thresholds at 8, 16, 24, 32, and 40 kHz were 59.9±5.05, 52.0±7.67, 73.8±8.64, 86.9±8.16, and 93.4±4.58 dB SPL, respectively ([Fig. 2c](#F2){ref-type="fig"}, P \< 0.001, one-way ANOVA with a Bonferroni correction). In comparison with WT littermates, the increase of ABR threshold in Cx26 cKO mice at 8, 16, 24, 32, and 40 kHz was 15.3±5.05, 16.7±7.67, 38.5±8.64, 45.7±8.16, and 46.9±4.58 dB SPL, respectively ([Fig. 2d](#F2){ref-type="fig"}). The increase at high-frequencies was larger. The thresholds were elevated by 30--45 dB SPL at frequencies above 24 kHz. The ABR threshold was also increased in heterozygous Cx26 cKO mice ([Fig. 2c&d](#F2){ref-type="fig"}). However, the increases were less than those in homozygous mice. The ABR thresholds at 24, 32, and 40 kHz were 51.8±5.73, 72.5±6.18, and 77.1±7.35 dB SPL, respectively (P \< 0.001, one-way ANOVA with a Bonferroni correction). The threshold was increased by 15--30 dB at frequencies above 24 kHz ([Fig. 2d](#F2){ref-type="fig"}).

Reduction of distortion product otoacoustic emission {#S5}
----------------------------------------------------

[Figure 3](#F3){ref-type="fig"} shows that targeted-deletion of Cx26 in DCs and OPCs significantly reduced DPOAE, which reflects activity of active cochlear amplification *in vivo*. The distortion product of 2f~1~--f~2~ at f~0~ of 20 kHz was almost at the noise level and was 6.92±6.37, 4.47±3.43, and 11.9±7.89 dB SPL at the stimulus level of 40, 50, and 60 dB SPL, respectively ([Fig. 3a&c](#F3){ref-type="fig"}). In comparison with WT littermates, the DPOAEs were reduced by 15.3±6.92, 30.2±4.47, and 30.9±7.89 dB at the stimulus level of 40, 50, and 60 dB SPL, respectively (P \< 0.001, one-way ANOVA with a Bonferroni correction). The decrease was larger at higher stimulus levels ([Fig. 3d](#F3){ref-type="fig"}). The decrease was also larger at higher frequencies ([Fig. 3b](#F3){ref-type="fig"}). The DPOAEs at 16 and 20 kHz were reduced by 15.8±7.23 and 30.9±7.89 dB, respectively (P\<0.001, one-way ANOVA with a Bonferroni correction). The DPOAE at 8 kHz in Cx26 cKO mice was also reduced by 3.69±4.61 dB. However, the decrease was not significant (P=0.13, one-way ANOVA). The DPOAE in heterozygous Cx26 cKO mice was also reduced ([Fig. 3b--d](#F3){ref-type="fig"}). The decrease at the stimulus level of 50 and 60 dB SPL was about 10 dB SPL (P \< 0.001, one-way ANOVA with a Bonferroni correction), which was less than that in homozygous Cx26 cKO mice ([Fig. 3c&d](#F3){ref-type="fig"}). The decrease was also larger at high frequencies ([Fig. 3b](#F3){ref-type="fig"}). The decrease at 16 and 20 kHz in the heterozygous mice was 8.95±7.01 and 13.3±7.19 dB, respectively (P\<0.001, one-way ANOVA with a Bonferroni correction).

No apparent cell degeneration in the Cx26 cKO mouse cochlea {#S6}
-----------------------------------------------------------

Targeted-deletion of Cx26 in DCs and OPCs did not cause apparent hair cell loss and cell degeneration in the inner ear. [Figure 4a](#F4){ref-type="fig"} shows that hair cell loss in Cx26 cKO mice was less than 5% at P30--60 and was not significantly different from WT mice. In particular, there was no signification hair cell loss at the high-frequency region (P \> 0.05, one-way ANOVA). Spiral ganglion (SG) neurons also had no apparent degeneration in Cx26 cKO mice ([Fig. 5](#F5){ref-type="fig"}). In comparison with WT littermates, the density of SG neurons in Rosenthal's canal was not significantly reduced in Cx26 cKO mice (P \> 0.05, one-way ANOVA, [Fig. 5b](#F5){ref-type="fig"}).

Normal cochlear microphonics and endocochlear potentials {#S7}
--------------------------------------------------------

Cochlear microphonics (CM) is the auditory receptor potential and is produced by hair cell mechanoelectrical transduction channel activity and EP driving force. CM in Cx26 cKO mice was normal ([Fig. 4b](#F4){ref-type="fig"}). Cx26 cKO mice also had normal endocochlear potential (EP). The recorded EP in WT, heterozygous, and homozygous mice was 92.0±2.31 mV (n=4), 95.0±0.58 mV (n=3), and 91.5±0.50 mV (n=2), respectively.

Left-shift of OHC nonlinear capacitance in Cx26 cKO mice {#S8}
--------------------------------------------------------

OHC electromotility associated NLC in Cx26 cKO mice retained a normal bell-shape but was shifted to the left in the hyperpolarization direction ([Fig. 6a](#F6){ref-type="fig"}). The voltage of peak capacitance (V~pk~) was significantly shifted from −73.8±2.14 mV in WT mice to − 90.9±2.22 mV in homozygous mice ([Fig. 6b](#F6){ref-type="fig"}, P=0.00004, one-way ANOVA with a Bonferroni correction). V~pk~ in heterozygous mice was −82.9±2.37 mV and also had a significant left-shift by \~10 mV (P=0.0003, one-way ANOVA with a Bonferroni correction). The V~pk~-shifting is larger in shorter OHCs ([Fig. 7](#F7){ref-type="fig"}). Linear regression analysis shows that the slope of V~pk~-shift with cell length is 2.33±0.55 (mean±SD, *r^2^*=0.22) and 1.60±0.49 mV/ μm (*r^2^*=0.32) in Cx26 cKO and WT mice, respectively ([Fig. 7a](#F7){ref-type="fig"}). The slopes had significant difference between Cx26 cKO and WT mice (P=0.004, Univariate analysis of variance). The V~pk~ at OHC lengths \<15, 15--20, and \>20 μm was left-shifted by −20.8±4.25, −14.6±2.72, and −10.37±3.81 mV, respectively, in Cx26 cKO mice ([Fig. 7b](#F7){ref-type="fig"}, P \< 0.05, one-way ANOVA with a Bonferroni correction).

However, there was no significant difference in linear capacitance (C~lin~) ([Fig. 6e](#F6){ref-type="fig"}). The C~lin~ in homozygous, heterozygous, and WT mice was 6.23±0.43, 6.65±0.27, and 6.73±0.34 pF, respectively (P=0.84, one-way ANOVA). Direct length measurement also shows that the average of lengths of recorded OHCs in WT and Cx26 cKO mice was 19.04±0.76 (n=24) and 18.09±2.14 μm (n=68), respectively. There was no significant difference between them (P=0.28, *t*-test).

No reduction in prestin expression and function {#S9}
-----------------------------------------------

Maximum charge (Q~max~) reflects the functional expression of prestin at the OHC lateral wall. Q~max~ in WT mice and heterozygous and homozygous Cx26 cKO mice was 0.72±0.04, 0.75±0.04, and 0.80±0.04 pC, respectively ([Fig. 6c](#F6){ref-type="fig"}). The Q~max~ in Cx26 cKO mice had a slight increase rather than decrease. However, the increase was not significant (P=0.13, one-way ANOVA). Real-time RT-PCR measurement also shows that the prestin expression at the transcription level was slightly increased rather than decreased in Cx26 cKO mice ([Fig. 8](#F8){ref-type="fig"}). The increase was also not significant (P=0.58, one-way ANOVA). There was no difference in valence *z* as well among WT mice and heterozygous and homozygous Cx26 cKO mice ([Fig. 6d](#F6){ref-type="fig"}, P=0.89, one-way ANOVA).

Discussion {#S10}
==========

We previously reported that *in vitro* uncoupling of gap junctions between DCs shifts OHC electromotility toward hyperpolarization and reduces the production of distortion products \[[@R17]\], indicating that supporting cells can play a role in the regulation of OHC electromotility. In this study, we selectively deleted Cx26 expression in DCs and OPCs *in vivo* ([Figs. 1](#F1){ref-type="fig"}& [Supplementary Fig. S1](#SD1){ref-type="supplementary-material"}). We found that the deletion shifted OHC electromotility to the left in the same hyperpolarization direction ([Figs. 6](#F6){ref-type="fig"}&[7](#F7){ref-type="fig"}) and caused DPOAE reduction and hearing loss ([Figs. 2](#F2){ref-type="fig"}&[3](#F3){ref-type="fig"}). These new findings provide direct evidence that cochlear supporting cells and gap junctions *in vivo* can regulate OHC electromotility to control active cochlear mechanics and hearing sensitivity.

Two active cochlear mechanics have been proposed: one is the prestin-based OHC electromotility \[[@R1], [@R3]--[@R5]\]; another is the stereocilium-based hair bundle movement \[[@R2], [@R27]--[@R29]\]. Deletion of Cx26 in DCs and OPCs shifted OHC electromotility toward hyperpolarization ([Figs. 6](#F6){ref-type="fig"}&[7](#F7){ref-type="fig"}). As previously reported \[[@R30]\], this shift can reduce the gain of OHC electromotility amplification. The left-shift can also alter the phase difference between OHC electromotility and active force generation \[[@R31]--[@R32]\]. To augment sound-evoked vibrations of the BM *in vivo*, maximal OHC contraction need coincide with maximal BM velocity in the direction of scala vestibule \[[@R33]--[@R34]\]. Other timing relationships will cause smaller amplification or even attenuation. Indeed, DPOAE was significantly reduced in Cx26 cKO mice ([Fig. 3](#F3){ref-type="fig"}), even prestin expression was not reduced ([Figs. 6c&d](#F6){ref-type="fig"} and 8). Recently, we found that Cx26 deficiency can alter supporting cell micromechanical property \[[@R35]\]. Supporting cell mechanical property change can alter OHC loading and membrane tension to shift OHC electromotility \[[@R36]--[@R37]\] and the phase between the OHC length change and the feedback of active force to the BM vibration \[[@R31]--[@R32]\]. As discussed above, these changes can eventually reduce the outcome of OHC electromotility and active cochlear amplification to induce hearing loss.

In Cx26 cKO mice, DPOAE reduction and hearing loss were larger and more severe at high frequencies ([Figs. 2](#F2){ref-type="fig"}&[3](#F3){ref-type="fig"}). However, Cx26 deletion in DCs and OPCs was uniform at the apical, middle, and basal turns ([Supplementary Fig. S1](#SD1){ref-type="supplementary-material"}). We previously found that Cx26 expression at the cochlear sensory epithelium is gradually reduced from the cochlear apex to base \[[@R15]\]. The basal turn has less Cx26 expression. The reduction is more pronounced in DCs and OPCs. So, targeted-deletion of Cx26 in DCs and OPCs may produce more severe function impairment at high frequencies. In addition, deletion of Cx26 in DCs and OPCs can reduce gap junctional coupling and may impair potassium recycling as well \[[@R19], [@R38]\]. Computer modeling shows that this can attenuate OHC transmembrane potential to reduce the activity of OHC electromotility, in particular, at the high frequency region \[[@R39]\]. Finally, shorter OHCs had larger shift in OHC electromotility ([Figs. 6](#F6){ref-type="fig"}&[7](#F7){ref-type="fig"}). These coincident changes strongly suggest that targeted-deletion of Cx26 in DCs and OPCs left-shifted OHC electromotility resulting into active cochlear mechanics reduction and hearing loss.

Frequency-dependent hearing loss ([Fig. 2](#F2){ref-type="fig"}) is also inconsistent with the EP reduction induced whole-frequency deafness. Moreover, Cx26 cKO mice retained normal CM and EP ([Fig. 4b](#F4){ref-type="fig"}), implying that the Cx26 cKO mice may retain normal hair cell transduction activity. These data further support the concept that targeted-deletion of Cx26 in DCs and OPCs causes OHC electromotility left-shifting rather than EP reduction to induce the reduction of active cochlear mechanics and hearing loss.

Cx26 mutations are a common genetic cause for nonsyndromic hearing loss \[[@R18]--[@R20]\]. However, the underlying deafness mechanisms still remain unclear. Previous mouse models with extensive deletion of Cx26 in the cochlea show that Cx26 deficiency can induce cochlear development disorder, hair cell degeneration, and congenital deafness \[[@R21]--[@R22], [@R40]\]. However, clinical phenotypes of Cx26 mutation are various. A large group (\~30%) of Cx26 mutation patients shows a progressive, late-onset hearing loss \[[@R18]--[@R20]\]. Our new study also found that hair cell degeneration is not a primary cause for Cx26 deficiency induced hearing loss \[[@R21]\]. Some mechanisms other than cochlear development disorder and hair cell degeneration must be engaged. In this study, we found that targeted-deletion of Cx26 in DCs and OPCs had hearing loss ([Fig. 2](#F2){ref-type="fig"}) but had no cochlear development disorders ([Figs. 1](#F1){ref-type="fig"}& [Supplementary Fig. S1](#SD1){ref-type="supplementary-material"}) and no significant hair cell and SG neuron degenerations ([Figs. 4](#F4){ref-type="fig"}&[5](#F5){ref-type="fig"}). OHC electromotility was left-shifted ([Figs. 6](#F6){ref-type="fig"}&[7](#F7){ref-type="fig"}) and DPOAE was reduced ([Fig. 3](#F3){ref-type="fig"}). These new findings provide not only new information about supporting cell dependence of active cochlear mechanics *in vivo* but also a new mechanism for Cx26 deficiency induced deafness, particularly, for late-onset hearing loss, which patients have a significant DPOAE reduction \[[@R41]--[@R42]\].

Materials and Methods {#S11}
=====================

Generation of Cx26 conditional KO mouse and genotyping {#S12}
------------------------------------------------------

*Cx26^loxP/loxP^* transgenic mice (EMMA, EM00245) \[[@R22]\] were crossed with *Prox1-CreER^T2^* mouse line \[[@R23]\]. *Prox1-CreER^T2^;Cx26^LoxP(+/−)^* mice were used for breeding. Tamoxifen (T5648, Sigma-Aldrich, St. Louis, MO) was administrated to all litters at postnatal day 0 (P0) by intraperitoneal injection (0.5 mg/10g × 3 days). Mouse genotyping was identified by PCR amplification of tail genomic DNA \[[@R22]--[@R23]\]. WT littermates were used as control. All experimental procedures were conducted in accordance with the policies of the University of Kentucky Animal Care & Use Committee.

In vivo physiological measurements {#S13}
----------------------------------

ABR, DPOAE, and CM recordings were performed in a double-wall sound isolated chamber by use of a Tucker-Davis ABR & DPOAE workstation with ES-1 high frequency speaker (Tucker-Davis Tech. Alachua, FL) \[[@R21]\]. Mice were anesthetized by intraperitoneal injection with a mixture of ketamine and xylazine (8.5 ml saline+1 ml Ketamine+0.55 ml Xylazine, 0.1 ml/10 g). Body temperature was maintained at 37--38°C. ABR was measured by clicks in alternative polarity and tone bursts (8 -- 40 kHz) from 80 to 10 dB SPL in a 5 dB step. The ABR threshold was determined by the lowest level at which an ABR can be recognized. If mice had severe hearing loss, the ABR test from 110 to 70 dB SPL was added. For CM recording, the electrode was ventrolaterally inserted deeply into the temporal bone \[[@R21]\]. The signal was amplified (50,000 x), filtered (3 -- 50 kHz), and averaged by 250 times.

For DPOAE recording, the test frequencies were presented by a geometric mean of f~1~ and f~2~ \[f~0~ = (f~1~ × f~2~)^1/2^\] from f~0~=4 to 20 kHz with a ratio of f~1~:f~2~=1:1.2. The distortion product was recorded from the L~1~/L~2~ level of 60/55 to 25/20 dB SPL with average of 150 times. A cubic distortion component of 2f~1~--f~2~ was measured.

EP was measured by a lateral-wall access. Mice were anesthetized and body temperature was maintained at 37--38°C. The cochlea was exposed by a ventral approach. Access to the endolymphatic compartment (scala media) of the middle turn was gained by thinning the bone over the spiral ligament and picking a small hole. The glass microelectrode was filled with a K^+^-based intracellular solution (140 KCl, 10 EGTA, 2 MgCl~2~, 10 HEPES in mM, pH7.2) and the EP was recorded with an AD/DA board (PCI- 6052E, National Instruments, Austin, TX, USA).

Immunofluorescent staining and confocal microscopy {#S14}
--------------------------------------------------

The cochlear tissue preparation and immunofluorescent staining were performed as previously reported \[[@R15]\]. Monoclonal mouse anti-Cx26 (Cat\# 33-5800, Invitrogen Corp), polyclonal rabbit anti-Cx30 (Cat\#71-2200, Invitrogen Corp), and polyclonal goat anti-prestin (Cat\# sc-22694, Santa Cruz Biotech Inc, CA) were used and visualized by secondary Alexa Fluor® 488 or 568 conjugated antibodies (Molecular Probes). The staining was observed under a confocal laser-scanning microscope.

Toluidine blue staining and spiral ganglion neuron accounting {#S15}
-------------------------------------------------------------

Consecutive cochlear paraffin sections were stained with toluidine blue using the conventional protocol \[[@R21]\]. To count the SG neurons, two neighboring sections separated by 40 μm were used to eliminate the possibility of double counting. Counting errors was corrected by Abercrombie's equation \[[@R43]\]: T/(T+D), in which T is the section thickness (10 μm) and D is the mean diameter (8.65 μm) of the SG neurons. The area of Rosenthal's canal in the cochlear sections was measured by NIH image software \[[@R21]\]. The densities of SG neurons in apical, middle, and basal turns were calculated by the number of SG neurons in the section divided by the area of Rosenthal's canal.

Real-time RT-PCR measurement of prestin expression {#S16}
--------------------------------------------------

As we previous reported \[[@R44]\], the cochlea was freshly isolated and homogenized. Its RNA was extracted by Absolutely RNA Miniprep Kit (Stratagene, La Jalla, CA), following manufacturer's instructions. The quality and quantity of total mRNAs were determined by NanoDrop ND-1000 Spectrophotometer (NanoDrop Technologies, Inc., Rockland, DE). The obtained mRNA was converted to cDNA by iScript^™^cDNA Synthesis Kit (Bio-Rad laboratories, Inc. Hercules, CA). Quantitative real-time PCR was performed by MyiQ real-time PCR detection system with iQ SYBR Green Super Mix kit (Cat. \#: 170822, Bio-Rad laboratories). The primers for prestin were 5′-GTT GGG TGG CAA GGA GTT TA-3′, 5′-ACA GGG AGG ACA CAA AGG TG-3′. The cycling condition of PCR amplification was 95°C 30 sec, 55°C 30 sec, and 72°C 30 sec, 45 cycles. Each cochlear sample was measured in triplicate and averaged. Universal 18S (QuantumRNATM 18S Internal Standards, Ambion Inc., Austin, TX) served as an internal control. The relative quantities of prestin expression were calculated from standard curves and normalized to the amount of 18S.

Patch-clamp recording of OHC nonlinear capacitance {#S17}
--------------------------------------------------

OHCs were freshly isolated from the cochlea \[[@R21], [@R44]\]. The classical patch clamp recording was performed under whole-cell configuration by using an Axopatch 200B patch clamp amplifier (Molecular Devices, CA) with jClamp (Scisft, New Haven, CT). Nonlinear capacitance (NLC) was measured by a two-sinusoidal method and fitted to the first derivative of a two-state Boltzmann function with jClamp and MATLAB \[[@R17], [@R44]\].

$$C_{m} = \mathit{NLC} + C_{\mathit{lin}} = Q_{\max}\frac{ze}{kT}\frac{\exp\left( \frac{- ze(V_{m} - V_{pk})}{kT} \right)}{\left( {1 + \exp\left( \frac{- ze(V_{m} - V_{pk})}{kT} \right)} \right)^{2}} + C_{\mathit{lin}}$$ where *Q~max~* is the maximum charge transferred, *V~pk~* is the peak of NLC, *z* is the number of elementary charge (*e*), *k* is Boltzmann's constant, and *T* is the absolute temperature. Membrane potential (*V~m~*) was corrected for electrode access resistance (*R~s~*).

Statistical analysis {#S18}
--------------------

Data were plotted by SigmaPlot and statistically analyzed by SPSS v13.0 (SPSS Inc.; Chicago, IL). Error bars represent SEM other than indicated in text.
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![Targeted deletion of Cx26 in DCs and OPCs in Cx26 cKO mice. **a--c**:Immunofluorescent labeling of the cochlear sensory epithelium for Cx26, Prestin, and Cx30 in the whole-mounting preparation. White-dashed lines represent OHC, DC and OPC area, where Cx26 labeling (green) is absent but Cx30 labeling (red color in panel **c**) remains in Cx26 cKO mice. **d,e**: Immunofluorescent staining of the cochlear cross-section for Cx26. OHCs are visualized by prestin labeling (red color). A white-dashed line box in panel **e** indicates OHCs, DCs, OPCs, and their neighboring area. OC: organ of Corti; LW: lateral wall; SLM: spiral limbus. **f--h**: High-magnification images of the boxed area. A white arrow in panel **g** indicates that the Cx26 labeling in the DC and OPC region is absent in Cx26 cKO mice. Three white arrows in panel **h** indicate 3 rows of OHCs. Scale bars = 50 μm in **a--e**; 10 μm in **f--h**.](nihms460252f1){#F1}

![Hearing loss in Cx26 cKO mice assessed by ABR recording. **a,b**: ABR waveforms recorded in Cx26 cKO and WT mice. The ABR was evoked by 24 kHz tone-bursts at postnatal day 45 (P45). **c**: Frequency-thresholds of ABR in homozygous and heterozygous Cx26 cKO mice and WT mice at P35**--**60. WT littermates served as a control group. **d**: Elevation of ABR thresholds in homozygous and heterozygous Cx26 cKO mice. Hearing loss is severe at high frequencies. Data are expressed as mean ± S.D; \*\*: P \< 0.001 as determined by one-way ANOVA with a Bonferroni correction](nihms460252f2){#F2}

![Reduction of acoustic emission in Cx26 cKO mice. **a**: Spectrum of acoustic emission recorded from Cx26 cKO mice and WT mice. Insets: Large scale plotting of 2f~1~--f~2~ and f~1~ peaks. The peak of DPOAE (2f~1~--f~2~) in Cx26 cKO mice was reduced but f~1~ and f~2~ peaks remained the same as those in WT mice. f~0~=20 kHz. **b**: Reduction of DPOAE in Cx26 cKO mice in frequency responses. DPOAEs were normalized to the WT mice. **c**: Reduction of DPOAE in Cx26 cKO mice in I/O plot. Dashed lines represent the noise levels of recording. **d**: Normalized reduction of DPOAE in homozygous and heterozygous Cx26 cKO mice. Data are expressed as mean ± S.D.; \*\*: P \< 0.001 as determined by one-way ANOVA with a Bonferroni correction.](nihms460252f3){#F3}

![Cx26 cKO mice have normal CM and no substantial hair cell loss. **a:** Hair cell accounting at Cx26 cKO mice. Mice were P30--60 old. WT littermates served as control. Insets I and II: The whole-mounting cochlear sensory epithelium was stained by phalloidin for hair cell accounting. Scale bars = 100 μm in I; 50 μm in II. **b:** CM responses of homozygous and heterozygous Cx26 cKO mice and WT mice. The CM was evoked by 90 dB SPL tone bursts. Insets: CM waveform recorded from WT and Cx26 cKO mice. Error bars represent S.D.](nihms460252f4){#F4}

![No spiral ganglion (SG) neuron degeneration in Cx26 cKO mice. **a**: SGs in Rosenthal's canal at the apical, middle, and basal turn. The sections were stained with toluidin blue. WT littermates served as control. The mice were P30--60 old. Scale bars = 30 μm. **b**: The density of SGs in Rosenthal's canal at the apical, middle, and basal turns. There is no significant difference in SG densities between Cx26 cKO mice and WT mice (P \> 0.05, one-way ANOVA). Data are expressed as mean ± S.D.](nihms460252f5){#F5}

![Left-shift of OHC NLC in Cx26 cKO mice. **a**: NLC recorded from Cx26 cKO and WT mice. Smooth lines represent fitting by the first derivative of Boltzmann equation. **b--e**: Parameters of NLC fitting. WT littermates served as a control group. Mice were P50--60 old. \*\*: P \< 0.001 as determined by one-way ANOVA with a Bonferroni correction. Data are expressed as mean ± S.D;](nihms460252f6){#F6}

![Large-shifting of NLC in shorter OHCs. **a**: Distribution of V~pk~ of NLC with OHC length. The solid lines represent linear fitting: y = 1.60x −104.3 and y = 2.33x −133.1 for WT and Cx26 cKO mice, respectively. **b**: V~p~--shifting in Cx26 cKO mice as function of OHC length. In comparison with WT, changes of the V~pk~ in Cx26 cKO mice were pooled in OHC length \<15, 15--20, \>20 μm ranges and averaged. \*: P\< 0.05, \*\*: P\< 0.01, one- way ANOVA with a Bonferroni correction. Data are expressed as mean ± S.D.](nihms460252f7){#F7}

![No prestin expression reduction in Cx26 cKO mice. Prestin expression at the transcriptional level was measured by real-time RT-PCR. WT littermates served as controls. Prestin expression in the Cx26 cKO mice appears slightly increased rather than decreased. However, the increase is not significant (P= 0.58, one-way ANOVA). Data are expressed as mean ± S.D.](nihms460252f8){#F8}
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